By engineering immune cells directly within the patient’s body, we aim to eliminate the barriers of traditional cell therapies. We are building an integrated discovery-to-development engine that connects vector innovation with translational impact. Join us to shape platform strategy, deliver differentiated candidates, and help patients faster.
As a proud new member of the AstraZeneca group, Esobiotec continues to set new standards in pioneering biotechnological research. With a shared vision to transform the future of medicine, our partnership uses AstraZeneca’s global reach and rich heritage in scientific innovation, amplifying Esobiotec’s unique culture of creativity and breakthrough advances in cell-based therapies and immunology. At Esobiotec, now backed by the resources and expertise of one of the world’s leading biopharmaceutical companies, you’ll find a dynamic, collaborative environment where scientific passion drives real-world impact. Be part of a team where your work will contribute to shaping the next generation of life-changing treatments and help us push the boundaries of science to improve patients’ lives worldwide.
We are seeking a Director/Associate Director to lead discovery and engineering of novel lentiviral vectors (LVV) from concept through preclinical candidate selection. You will refine our discovery strategy, build scalable screening platforms, and integrate developability and CMC thinking from the start. This role is highly cross-functional and product-focused, partnering closely with biological engineering, CAR/TCR discovery, nonclinical, safety, clinical, process development, analytics, and computational teams. Title will be commensurate with experience and demonstrated scope.